Cheap Broker Fees
Vaxart Inc is a biotechnology business based in the US. Vaxart shares (VXRT) are listed on the NASDAQ and all prices are listed in US Dollars. Vaxart employs 28 staff and has a trailing 12-month revenue of around USD$1.2 million.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Vaxart's stock price has had significant positive movement.
Its last market close was $6.88, which is 84.16% up on its pre-crash value of $1.09 and 607.96% up on the lowest point reached during the March crash when the stocks fell as low as $0.9718.
If you had bought $1,000 worth of Vaxart stocks at the start of February 2020, those stocks would have been worth $1,156.25 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $4,300.00.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$6.88|
|52-week range||$3.71 - $15.80|
|50-day moving average||$8.03|
|200-day moving average||$7.55|
|Wall St. target price||$12.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.48|
|1 week (2021-10-14)||-4.44%|
|1 month (2021-09-20)||-12.58%|
|3 months (2021-07-22)||-17.11%|
|6 months (2021-04-22)||19.44%|
|1 year (2020-10-22)||26.24%|
|2 years (2019-10-22)||1,866.28%|
|3 years (2018-10-22)||119.11%|
|5 years (2016-10-21)||355.63%|
|Revenue TTM||$1.2 million|
|Gross profit TTM||$-15,817,000|
|Return on assets TTM||-22.69%|
|Return on equity TTM||-45.05%|
|Market capitalisation||$869.4 million|
TTM: trailing 12 months
There are currently 18.9 million Vaxart shares held short by investors – that's known as Vaxart's "short interest". This figure is 16.1% up from 16.2 million last month.
There are a few different ways that this level of interest in shorting Vaxart shares can be evaluated.
Vaxart's "short interest ratio" (SIR) is the quantity of Vaxart shares currently shorted divided by the average quantity of Vaxart shares traded daily (recently around 3.0 million). Vaxart's SIR currently stands at 6.35. In other words for every 100,000 Vaxart shares traded daily on the market, roughly 6350 shares are currently held short.
However Vaxart's short interest can also be evaluated against the total number of Vaxart shares, or, against the total number of tradable Vaxart shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vaxart's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Vaxart shares in existence, roughly 150 shares are currently held short) or 0.1547% of the tradable shares (for every 100,000 tradable Vaxart shares, roughly 155 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vaxart.
We're not expecting Vaxart to pay a dividend over the next 12 months.
Vaxart's shares were split on a 1:11 basis on 13 February 2018. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaxart shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Vaxart shares which in turn could have impacted Vaxart's share price.
Over the last 12 months, Vaxart's shares have ranged in value from as little as $3.71 up to $15.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaxart's is 0.5134. This would suggest that Vaxart's shares are less volatile than average (for this exchange).
Vaxart, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI. 1 and GII. 4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc.
The second Bitcoin future ETF is set to go live Oct. 22. Here’s how to invest if you’re in Singapore.
Steps to owning and managing VanEck Bitcoin Strategy ETF units.
ProShares Bitcoin Strategy ETF is the first fund tied to the value of a cryptocurrency to trade on the major U.S. markets. Here’s how to invest if you’re in Singapore.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.